It's also interesting to note that the point of view that has been expressed often leads to the most expensive drugs, and they're also the most risky. I wonder if another member of the committee could explain what evidence there is to support the benefit-risk ratio in regard to some of these newer drugs versus the cost.
On May 9th, 2007. See this statement in context.